Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome
- 4 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (7), 2038-2049
- https://doi.org/10.1158/1078-0432.ccr-20-3262
Abstract
Purpose: Glioblastoma (GBM) immunotherapy clinical trials are generally initiated after standard-of-care treatment—including surgical resection, perioperative high-dose steroid therapy, chemotherapy, and radiation treatment—has either begun or failed. However, the impact of these interventions on the antitumoral immune response is not well studied. While discoveries regarding the impact of chemotherapy and radiation on immune response have been made and translated into clinical trial design, the impact of surgical resection and steroids on the antitumor immune response has yet to be determined. Experimental Design: We developed a murine model integrating tumor resection and steroid treatment and used flow cytometry to analyze systemic and local immune changes. These mouse model findings were validated in a cohort of 95 patients with primary GBM. Results: Using our murine resection model, we observed a systemic reduction in lymphocytes corresponding to increased tumor volume and decreased circulating lymphocytes that was masked by dexamethasone treatment. The reduction in circulating T cells was due to reduced CCR7 expression, resulting in T-cell sequestration in lymphoid organs and the bone marrow. We confirmed these findings in a cohort of patients with primary GBM and found that prior to steroid treatment, circulating lymphocytes inversely correlated with tumor volume. Finally, we demonstrated that peripheral lymphocyte content varies with progression-free survival and overall survival, independent of tumor volume, steroid use, or molecular profiles. Conclusions: These data reveal that prior to intervention, increased tumor volume corresponds with reduced systemic immune function and that peripheral lymphocyte counts are prognostic when steroid treatment is taken into account.Keywords
Other Versions
Funding Information
- NIH (R01 NS109742)
- NIH (F31 NS101771)
- NIH (F32 CA243314)
This publication has 27 references indexed in Scilit:
- Tryptophan Metabolism Contributes to Radiation-Induced Immune Checkpoint Reactivation in GlioblastomaClinical Cancer Research, 2018
- Current state of immunotherapy for glioblastomaNature Reviews Clinical Oncology, 2018
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With GlioblastomaJAMA, 2017
- Recurrent glioma clinical trial, CheckMate-143: the game is not over yetOncotarget, 2017
- Immune Checkpoint in Glioblastoma: Promising and ChallengingFrontiers in Pharmacology, 2017
- Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune EvasionThe International Journal of Cell Cloning, 2016
- Corticosteroids compromise survival in glioblastomaBrain, 2016
- Dealing with Danger in the CNS: The Response of the Immune System to InjuryNeuron, 2015
- Immunocompetent murine models for the study of glioblastoma immunotherapyJournal of Translational Medicine, 2014
- Impact of Temozolomide on Immune Response during Malignant Glioma ChemotherapyJournal of Immunology Research, 2012